Navigation Links
TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai
Date:11/10/2008

LA JOLLA, Calif., Nov. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has agreed to sell its Alzheimer's disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer's disease genetics research program focused on the discovery of Alzheimer's disease targets using whole-genome family-based association screening.

"We are pleased to announce the sale of our genetics program to our long-time partner, Eisai," said Ev Graham, acting chief executive officer of TorreyPines Therapeutics. "The sale of this asset furthers our transition to a development-only company and enables us to focus our resources on advancing our clinical stage assets: tezampanel, NGX426 and NGX267. As a leader in treating Alzheimer's disease we believe Eisai is well positioned to capitalize on the discoveries from the genetics program."

The genetics program is one of two TorreyPines discovery programs focused on Alzheimer's disease, the other being a gamma secretase modulator (GSM) program. Recently, a lead compound from the GSM program has been shown to reduce plaque load and Abeta peptide levels in the brains of Tg2576 Alzheimer's disease model mice after seven months of oral dosing. TorreyPines is currently seeking a partner for this program.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's go
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Follow, THE WOODLANDS, Texas, Feb. 20 Lexicon,Pharmaceuticals, ... quarter and,year end 2007 financial results on Thursday, March ... hold a conference call to,discuss its clinical development progress, ... 5:00 p.m. Eastern Time on March 6, 2008., ...
... ... 2006, to RMB17.9 ... to RMB180.2 ... ...
... Unprecedented ... Accuracy, PITTSBURGH, Feb. ... has been published in,January 2008 edition of the Federal Register as a ... known as RCRA (Resource,Conservation and Recovery Act). This updated version of the ...
Cached Biology Technology:Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 16Newly Published EPA RCRA Method 6800 Supports AIT Technology 2
(Date:7/10/2014)... July 3, 2014 According to ... Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, ... Security and Banking & Finance), and Geography - Global ... MarketsandMarkets, the global Fingerprint Sensors Market is projected to ... CAGR of 16.8% from 2014 to 2020. ...
(Date:7/10/2014)... GOTHENBURG, Sweden , July 7, 2014 ... won its first major design win (DW). A Chinese Top ... with the planned start of mass production in October 2014. ... with a Chinese Top 5 smartphone OEM, which has a ... 2014 and a target sales volume for this phone of ...
(Date:7/10/2014)... July 8, 2014 Fingerprint ... new design win (DW). An Asian OEM has selected FPC1021 ... production start in August 2014.   FPC is ... which has a planned date for start of mass production ... order of SEK 5M, for delivery in the first half ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... Inc.,(OTC Bulletin Board: BKYI), a leader in wireless public ... the,company,s Chief Executive Officer, Michael DePasquale, is featured in ... interview gives viewers an overview of the company, and ... To view the clip in its entirety, ...
... of its kind in the United States, researchers have ... outperforms current biofuels sources by a lot. Using ... U.S. could significantly reduce the acreage dedicated to biofuels ... The new findings, from researchers at the University ...
... Berkeley, virologist and an assistant professor in the Department of ... Foundation grant, an award given to innovative young scientists in ... up to $1 million over five years, will go to ... a tool to study the inner workings of human cells. ...
Cached Biology News:[video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.net's 3-Minute Press Show 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 3UC Berkeley virologist named Keck Distinguished Young Scholar 2
AedestaTM Animal Organ/Tissue Perfusion Soln....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
... complementary RNA Spikes for the normalization and ... array printing and for protocol assessment and ... hybridization stringency and background. Normalize Cy3 and ... Oligo Spots, and complementary RNA Spikes for ...
Biology Products: